Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00025662 · OUTCOME

Acute GVHD (Any Grade) Using the CIBMTR Grading System.

Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS · Source last updated 2016-10-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
100 days from transplant

What was measured

Proportion of patients with acute GVHD, grade 1 to 4

Analysis population: All 22 subjects who received the selectively depleted transplant

Groups in this outcome

RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants

Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants22

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants54.5Not reported33.775.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        33.7
        upper Limit
        75.4
        value
        54.5
denoms
  1. counts
    1. group Id
      OG000
      value
      22
    units
    Participants
description
Proportion of patients with acute GVHD, grade 1 to 4
dispersion Type
95% Confidence Interval
groups
  1. description
    Ex vivo selective depletion of alloreactive donor T lymphocytes utilizing RFT5-SMPT-dgA, a specific anti-interleukin-2 receptor immunotoxin in HLA-matched, nonmyeloablative, peripheral blood stem cell transplantation for hematologic malignancies in older adults
    id
    OG000
    title
    RFT5-SMPT-dgA, an Anti-interleukin, Used in Transplants
param Type
NUMBER
population Description
All 22 subjects who received the selectively depleted transplant
reporting Status
POSTED
time Frame
100 days from transplant
title
Acute GVHD (Any Grade) Using the CIBMTR Grading System.
type
OTHER_PRE_SPECIFIED
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice